Showing results (91-100 of 154) with videos related to

Sort By:
Pageof 16
Biochemical Pharmacology|July 25, 2007
Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxiaChris P Guise, Anderson T Wang, Anke Theil, et al.
Frontiers in Pharmacology|October 4, 2018
Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell CulturesCho R Hong, Gib Bogle, Jingli Wang, et al.
Cancer Gene Therapy|September 8, 2023
Clonal dynamics limits detection of selection in tumour xenograft CRISPR/Cas9 screensTet Woo Lee, Francis W Hunter, Peter Tsai, et al.
Dalton Transactions (Cambridge, England : 2003)|July 15, 2004
Anionic carbonato and oxalato cobalt(III) nitrogen mustard complexesPeter R Craig, Penelope J Brothers, George R Clark, et al.
Cancer Chemotherapy and Pharmacology|December 17, 2009
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumorsMichael B Jameson, Danny Rischin, Mark Pegram, et al.
Cancer Chemotherapy and Pharmacology|December 24, 2002
Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)Bronwyn G Siim, Alan E Lee, Sahar Shalal-Zwain, et al.
Plos Computational Biology|October 26, 2018
An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroidsXinjian Mao, Sarah McManaway, Jagdish K Jaiswal, et al.
Radiation Research|May 26, 2007
Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustardsWilliam R Wilson, Kevin O Hicks, Susan M Pullen, et al.
BMC Cancer|October 11, 2011
A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patientsMark J McKeage, Yongchuan Gu, William R Wilson, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2007
Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamineKevin O Hicks, Hilary Myint, Adam V Patterson, et al.
Pageof 16